The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
He holds a Bachelor’s Degree in Science and has joined the company in 2012 and has over 10 years of experience in pharmaceutical industry
Two main objectives are: Accelerate novel technologies and products for global markets; and Connect academia and industry, creating synergy for faster advancement of the Bioprotection sector
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Formula attenuates 99% of 365 coronaviruses in computer models
Subscribe To Our Newsletter & Stay Updated
